MannKind Corporation Stock News

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), today announced that Chief Executive Officer Michael Castagna will participate in a panel focused on innovation across chronic respiratory diseases at the Chardan Healthcare Conference. Management will also participate in one-on-one meetings with investors during the conference.

Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind's Technosphere ® inhalation technology MannKind to receive an equity interest and potential royalties while providing pharmaceutical development and manufacturing support through completion of a Phase 1b clinical study DANBURY, Conn. and WESTLAKE VILLAGE, Calif.

Achieved three major catalysts to drive future growth: Launched the pediatric indication of Afrezza ® following FDA approval FUROSCIX ReadyFlow™ autoinjector approved for treatment of edema in HF and CKD Positive nintedanib DPI Phase 1b data in IPF patients validates continued Phase 2 advancement Encouraging early momentum in Afrezza pediatric launch 1 in 3 of the top 100 pediatric insulin writ...

We also report on an experimental diagnostic approach that can ​detect tuberculosis exposure and infection at an earlier stage than current methods.

MNKD Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety & Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF

DANBURY, Conn. and WESTLAKE VILLAGE, Calif.

MannKind announces FDA approval of Furoscix ReadyFlow™, the first & only autoinjector delivering IV-equivalent diuretic therapy for the treatment of edema